advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010; 28: 5240–5246.

21. Horinouchi H, Kubota K, Itani H et al. Short hydration in chemotherapy containing cisplatin (>/=75 mg/m^2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 2013; 43: 1105–1109.

22. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–3551.

High level of chromosomal instability in circulating tumor cells of *ROS1*-rearranged non-small-cell lung cancer

E. Pailler[1,2], N. Auger[3], C. R. Lindsay[1,2], P. Vielh[1,2,3], A. Islas-Morris-Hernandez[2], I. Borget[4], M. Ngo-Camus[5], D. Planchard[5], J.-C. Soria[1,5], B. Besse[5,†] & F. Farace[1,2,†*]

[1]INSERM U981 "Identification of Molecular Predictors and new Targets for Cancer Treatment", University of Paris-Sud XI, Gustave Roussy, Villejuif; [2]Translational Research Laboratory, Gustave Roussy, Villejuif; Departments of [3]Biopathology; [4]Biostatistics and Epidemiology; [5]Medicine, Gustave Roussy, Villejuif, France

Background: Genetic aberrations affecting the *c-ros oncogene 1* (*ROS1*) tyrosine kinase gene have been reported in a small subset of patients with non-small-cell lung cancer (NSCLC). We evaluated whether *ROS1*-chromosomal rearrangements could be detected in circulating tumor cells (CTCs) and examined tumor heterogeneity of CTCs and tumor biopsies in *ROS1*-rearranged NSCLC patients.

Patients and methods: Using isolation by size of epithelial tumor cells (ISET) filtration and filter-adapted-fluorescence *in situ* hybridization (FA-FISH), *ROS1* rearrangement was examined in CTCs from four *ROS1*-rearranged patients treated with the ROS1-inhibitor, crizotinib, and four *ROS1*-negative patients. *ROS1*-gene alterations observed in CTCs at baseline from *ROS1*-rearranged patients were compared with those present in tumor biopsies and in CTCs during crizotinib treatment. Numerical chromosomal instability (CIN) of CTCs was assessed by DNA content quantification and chromosome enumeration.

Results: *ROS1* rearrangement was detected in the CTCs of all four patients with *ROS1* rearrangement previously confirmed by tumor biopsy. In *ROS1*-rearranged patients, median number of *ROS1*-rearranged CTCs at baseline was 34.5 per 3 ml blood (range, 24–55). In *ROS1*-negative patients, median background hybridization of *ROS1*-rearranged CTCs was 7.5 per 3 ml blood (range, 7–11). Tumor heterogeneity, assessed by *ROS1* copy number, was significantly higher in baseline CTCs compared with paired tumor biopsies in the three patients experiencing PR or SD ($P < 0.0001$). Copy number in *ROS1*-rearranged CTCs increased significantly in two patients who progressed during crizotinib treatment ($P < 0.02$). CTCs from *ROS1*-rearranged patients had a high DNA content and gain of chromosomes, indicating high levels of aneuploidy and numerical CIN.

Conclusion: We provide the first proof-of-concept that CTCs can be used for noninvasive and sensitive detection of *ROS1* rearrangement in NSCLC patients. CTCs from *ROS1*-rearranged patients show considerable heterogeneity of *ROS1*-gene abnormalities and elevated numerical CIN, a potential mechanism to escape ROS1-inhibitor therapy in *ROS1*-rearranged NSCLC tumors.

Key words: *ROS1*-rearranged non-small-cell lung cancer, circulating tumor cells, filtration enrichment, FA-FISH, predictive biomarker

introduction

Lung cancer is the leading global cause of cancer death, with non-small-cell lung cancer (NSCLC) patients accounting for ~80% of its cases. A new paradigm for NSCLC treatment

Correspondence to: Dr Françoise Farace, University of Paris-Sud XI, INSERM U981, Translational Research Laboratory, Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France. Tel: +33-1-42-11-51-98; E-mail: francoise.farace@gustaveroussy.fr

†Both authors contributed equally to the study.

recently emerged with the discovery of molecularly defined subsets of patients who can be treated effectively by therapies targeted to a specific driver gene [1, 2]. Small-molecule tyrosine kinase inhibitors (TKI) tailored for oncogenic 'driver' alterations have shown unprecedented success in molecularly selected NSCLC patients harboring *epidermal growth factor receptor* (*EGFR*) mutations (EGFR TKI: gefitinib, erlotinib, and afatinib), or *anaplastic lymphoma kinase* (*ALK*) fusion gene (ALK TKI: crizotinib, alectinib, ceritinib) [3, 4].

C-ros oncogene 1 (*ROS1*) fusion genes have recently been identified in ~1% of NSCLC [5, 6]. Rearrangement leads to fusion of the *ROS1* gene on chromosome 6 with a number of different genetic partners, a process that can drive cellular transformation and constitutive ROS1 kinase activity [7]. *ROS1*-rearranged NSCLCs have been associated with adenocarcinoma histology, never smokers, and younger patient age at diagnosis—clinical features that are also associated with *EGFR/ALK* genetic modifications [5]. It has also been reported that patients with *ROS1*-rearranged NSCLC can benefit from crizotinib therapy; clinical trials are ongoing in this population to evaluate this further [6, 8].

Patient genotyping and eligibility for targeted treatment is currently identified using tumor biopsy, a process that can be limited by small sample size and technical difficulties with biopsy. A single biopsy sample may also not reflect the genetic diversity of a patient's tumor [9]. Recent pioneering studies have shown differences in tumor mutational profiles within distinct regions of the primary tumor and respective metastases, demonstrating intratumor heterogeneity in both space and time [9]. The development of efficient, noninvasive methods to identify molecular alterations and biomarkers of tumor heterogeneity will be a key future challenge which circulating tumor cells (CTCs) have the potential to exploit.

CTCs migrate from primary tumor or metastatic sites and are an easily accessible, noninvasive source of tumor material [10–12]. Molecular characterization of CTCs can shed light on tumor heterogeneity, genomic diversity of metastatic disease, and underlying oncogenic alterations, thereby serving as a predictive biomarker of drug sensitivity [13]. Using the CellSearch platform, a method based on detecting EpCAM-positive epithelial cells, CTC levels were shown to have prognostic significance in several metastatic tumors, including NSCLC [14–16]. A few studies have demonstrated the feasibility of CTC assays for predictive biomarker detection and, previously, we and another group reported the detection of *ALK* rearrangement in CTCs enriched by filtration in *ALK*-positive NSCLC patients [17, 18]. Currently, the genomic heterogeneity of CTCs remains poorly characterized. Numerical chromosomal instability (CIN) is a type of genomic instability which is defined by a high rate of gain/loss of whole chromosomes, or fractions of chromosomes. It causes widely heterogeneous chromosomal aberrations as well as aneuploidy and intratumor heterogeneity [19]. It is also known to be associated with poor patient outcome and drug resistance in multiple cancer types, but has never been explored in CTCs [19–22].

Here, we offer a proof-of-concept that *ROS1* rearrangement can be detected in CTCs from *ROS1*-rearranged NSCLC patients using filter-adapted-fluorescent *in-situ* hybridization (FA-FISH), a FISH assay optimized for CTC analysis on filters [18]. We further characterize the heterogeneity of these CTCs through assessment of their CIN.

methods

patients

ROS1-rearranged and *ROS1*-negative patients were recruited at Gustave-Roussy, Paris. All *ROS1*-rearranged patients were offered crizotinib treatment 'off label'. Informed written consent for blood sample collection was obtained from patients (IDRCB2008-A00585-50). The study was approved by local institutional board and ethics committees.

FISH on tumor tissue

FISH for tumor biopsy was carried out as described in the supplementary Methods, available at *Annals of Oncology* online. The *ROS1* Break Apart kit consists of two probes adjacent to the 3′ (green) and 5′ (red) ends of *ROS1*. In cells with native *ROS1* status, overlapping of probes results in a fused (3′/5′, yellow) signal. The two characteristic *ROS1*-rearrangement split patterns are the split of the 3′ and 5′ probes (a distance >2 signal diameters is considered as a split), or an isolated, single or amplified, 3′ signal. Signals were enumerated in at least 50 tumor nuclei and FISH-positive cases were defined as those with >15% of split or isolated signals [5, 6].

CTC detection by CellSearch and enrichment by ISET filtration

Enumeration of CTCs using the CellSearch system (Johnson and Johnson, Raritan, NJ) was done according to the manufacturer's protocol [14, 15]. CTC enrichment by isolation by size of epithelial tumor cells (ISET) (Rarecells, Paris, France) was carried out as previously reported [15].

immunofluorescent staining and FA-FISH of filtration-enriched CTCs

Immunofluorescent staining and FA-FISH on filters was used as previously reported [18] and described in the supplementary Methods, available at *Annals of Oncology* online. FA-FISH was carried out with the Vysis 6q22 *ROS1* Break Apart FISH probe RUO Kit (Abbott Molecular, Inc., Des Plaines, IL) as shown in the supplementary Figure S1, available at *Annals of Oncology* online.

immunofluorescent staining and DNA quantification of filtration-enriched CTCs using Hoechst 33342 staining

Enumeration of CTCs present on filters was done by combining immunofluorescence staining and cytomorphological examination as previously reported [18] and described in the supplementary Methods, available at *Annals of Oncology* online. DNA quantification is described in the supplementary Methods and Figure S2, available at *Annals of Oncology* online.

multi-FA-FISH of filtration-enriched CTCs

The method and CIN degree grade determination are detailed in the supplementary Methods, available at *Annals of Oncology* online. Multi-FA-FISH was carried out with the AneuVysion Multicolor DNA Probe Kit (Abbott Molecular, Inc.).

cell lines

Cell lines and culture methods are described in the supplementary Methods, available at *Annals of Oncology* online.

statistical methods

Statistical methods are described in the supplementary Methods, available at *Annals of Oncology* online.

B

Patients	Sex	Age	Smoking status	BOR	PFS	Tumor Biopsy origin[a]	Tumor % of rearranged cells	CTCs Sample	CTCs Rearranged CTCs detected by ISET (/3 ml)	CTCs CTCs counts by Cellsearch (/7.5 ml)
P1	F	74	0	SD	3.3	Lung (MT)	20%	Day 1	24	NA
								Day 75[b]	39	0
P2	M	66	0	PR	6.8+	Pleura (MT)	44%	Day 1	55	0
								Day 40	32	0
P3	F	37	16	PD	1.5	Node (MT)	60%	Day 1	28	2
								Day 45	29	6
P4	M	63	2	PR	7.1+	Node (MT)	82%	Day 1	41	2
								Day 80	22	0
PN1	M	35	0	–	–	Pleura (MS)	–	–	7	0
PN2	M	55	0	–	–	Lung (PT)	–	–	8	6
PN3	F	43	10	–	–	Lung (PT)	–	–	7	0
PN4	F	68	40	–	–	Node (MS)	–	–	11	1

Figure 1. (A) Treatment lines and quantification of *ROS1*-rearranged CTCs in the four *ROS1*-rearranged patients. Blue dotted lines indicate the median value of *ROS1*-rearranged CTCs detected in 3 ml blood in control *ROS1*-negative patients. Red dashed lines indicate the median value of *ROS1*-rearranged CTCs detected in 3 ml blood in *ROS1*-rearranged patients. Asterisks show the day of *ROS1*-rearrangement diagnosis in tumor biopsy. Arrows indicate treatment is ongoing. The black line indicates that the patient died. (B) *ROS1*-rearranged cells in tumor and in CTCs of *ROS1*-rearranged and *ROS1*-negative patients. BOR, best overall response; F, female; M, male; MT, metastasis; NA, non-available; P, *ROS1*-rearranged patients; PD, progressive disease; PFS, progression-free survival; PN, *ROS1*-negative patient; PR, partial response; PT, primary tumor; SD, stable disease. [a]Tumor biopsy obtained from primary tumor or metastasis. [b]P1 received discontinuous crizotinib treatment; at the time of the study, patient had discontinued crizotinib for 2 weeks.

Figure 2. Detection of *ROS1*-gene alterations in CTCs and tumor specimens from *ROS1*-rearranged patients. (A) Examples of *ROS1*-rearranged tumor cells in the tumor biopsy specimen and CTCs from patient P2. Green and red arrows show 3′ and 5′ *ROS1*-rearrangement extremities, respectively. Scale: white bars = 10 μm. (B) Tumor heterogeneity evaluated by enumerating *ROS1*-gene copies in tumor cells harboring a *ROS1*-rearrangement or only a gain of *ROS1* native copies in baseline CTCs and tumor biopsies.

A

Rearranged CTCs

B

CTCs with only gain

Figure 3. Numbers of *ROS1*-gene copies in *ROS1*-rearranged CTCs and CTCs harboring only gain at baseline and under crizotinib treatment in *ROS1*-rearranged patients. (A) Numbers of *ROS1*-gene copies in *ROS1*-rearranged CTCs from *ROS1*-rearranged patients. (B) Numbers of *ROS1*-gene copies in CTCs harboring only gain from *ROS1*-rearranged patients.

results

Four patients (P1-P4) with *ROS1*-rearranged NSCLC treated by crizotinib were recruited to the study. Two patients (P2, P4) displayed a partial response (PR) to crizotinib for 6.8 and 7.1 months, respectively (Figure 1). One patient (P1) had stable disease (SD) for 3 months, and one patient (P3) had disease progression (PD). Previous number of treatment lines ranged from 1 to 5, with PRs observed in the two patients who had received the smallest number of previous treatment lines (Figure 1A).

Percentage of *ROS1*-rearranged cells in metastatic biopsies ranged from 20% to 82% (Figure 1B). Using CellSearch, CTC values at baseline were 0, 2, and 2 CTCs per 7.5 ml blood in patients P2, P3, and P4, respectively (not carried out in P1) (Figure 1B). While receiving crizotinib, patients P1, P2, and P4

had no CTCs detected by CellSearch; CTCs increased to 6 per 7.5 ml blood in P3 who did not respond to crizotinib.

ROS1 rearrangement was next examined in CTCs using ISET filtration and combined immunofluorescent staining and FA-FISH, as previously reported [18]. Median number of *ROS1*-rearranged CTCs at baseline was 34.5 per 3 ml blood (range, 24–55) in *ROS1*-rearranged patients. In P2 and P4, who responded to crizotinib, *ROS1*-rearranged CTCs dropped from 55 at baseline to 32 per 3 ml at day 40 in P2, and from 41 at baseline to 22 per 3 ml at day 80 in P4. In P1, who had initially SD, *ROS1*-rearranged CTCs increased from 24 to 39 per 3 ml blood 2 weeks after crizotinib discontinuation, a change consistent with the patient's radiological PD by computed tomography (CT) (Figure 1). In P3, who did not respond to treatment, the level of *ROS1*-rearranged CTCs was stable: 28/3 ml blood at baseline, and 29/3 ml blood at crizotinib interruption. The median number of *ROS1*-rearranged CTCs was 7.5 per 3 ml blood (range, 7–11) in *ROS1*-negative patients (representing background hybridization of *ROS1* probes in FA-FISH experiments). Overall, these data showed that *ROS1* rearrangement could be specifically detected in CTCs from *ROS1*-rearranged NSCLC patients undergoing crizotinib treatment. Variations in *ROS1*-rearranged CTC levels were consistent with clinical evolution in three of four patients.

Next, patterns of *ROS1* rearrangement were examined within paired biopsy specimens and CTCs of *ROS1*-rearranged patients (supplementary Table S1, available at *Annals of Oncology* online). As previously reported, two split patterns were detected in tumor biopsies consisting in either the split of green and red signals or isolated green signals [5, 6]. In contrast to tumor biopsies, both types of split pattern were identified in *ROS1*-rearranged CTCs, with gain of native *ROS1* copies far more prevalent (Figure 2A, supplementary Table S1, available at *Annals of Oncology* online). This included an important subset of CTCs exclusively harboring a gain of native *ROS1* copies (supplementary Table S1, available at *Annals of Oncology* online). In CTCs with both types of *ROS1* split pattern, tumor heterogeneity, as assessed by *ROS1* copy number, was significantly higher in CTCs compared with paired tumor biopsy in the three patients who experienced PR (P2, P4) or SD (P1) ($P < 0.0001$) (Figure 2B).

We next evaluated the effect of crizotinib on *ROS1*-gene copy number. The number of *ROS1*-gene copies present in *ROS1*-rearranged cells increased significantly during treatment in the two patients (P1, P3) who had tumor progression ($P < 0.05$) (Figure 3A). No change was observed in the number of *ROS1*-gene copies present in cells harboring only gains (Figure 3B). Taken together, these results suggested that spatial heterogeneity at treatment baseline (assessed by *ROS1* copy number between primary tumor and CTCs pretreatment) did not impede response, but subsequent temporal heterogeneity of *ROS1* copy number (assessed in CTCs before and during treatment) emerged in parallel with tumor progression.

As *ROS1* FISH patterns within CTCs were strongly suggestive of the presence of highly aneuploid cells, we sought to characterize CTCs from *ROS1*-rearranged patients by means of two tests (DNA quantification by Hoechst 33342 measurement, multi-FISH assay) used to assess aneuploidy and numerical CIN status. CTCs from *ROS1*-rearranged patients were identified on filters as previously reported [18], and their DNA content determined

Figure 4. CIN status assessment in baseline CTCs from *ROS1*-rearranged patients. (A) Examples of CTCs with distinct epithelial and mesenchymal marker expression and high DNA content in a representative *ROS1*-rearranged patient. (B) Examples of hybridized WBCs and CTCs using fluorescently labeled probes. Green spots indicate probe hybridization at chromosome LSI 13 and CEP X, red spots at LSI 21 and CEP Y and blue spots at CEP 18. Scale: white bars = 10 μm. (C) Distribution of baseline CTC ploidy.

relative to WBCs (Figure 4A, supplementary Table S2 and Figure S2, available at *Annals of Oncology* online). Immunofluorescence of CTCs revealed distinct epithelial and mesenchymal marker expression patterns, as well as high DNA content (Figure 4A). Numerical CIN status in CTCs from *ROS1*-

rearranged patients was further characterized using the AneuVysion multi-FISH assay, which is used in prenatal diagnosis to enumerate chromosomes 13, 18, 21, X, and Y. Examples of chromosome 13, 18, 21, X and Y enumerations in CTCs are shown (Figure 4B). Patients P1, P2, and P4 had similar CTC

profiles characterized by various stages of ploidy and the presence of highly aneuploid cells, while patient P3 had less CTCs bearing high ploidy (Figure 4C). Mean ploidy of CTCs in patients P1, P2, and P4 was approximately seven, while it was of 4.5 in patient P3 (supplementary Table S3, available at *Annals of Oncology* online). The four patients had the maximal numerical CIN score of 3.

discussion

Using an approach, we previously described for *ALK*-rearrangement detection [18], here we report for the first time that *ROS1* rearrangement can be detected in CTCs of patients with *ROS1*-rearranged NSCLC. The median number of *ROS1*-rearranged CTC levels was 34.5 per 3 ml blood at baseline in *ROS1*-rearranged patients. The level of nonspecific hybridization of *ROS1* probes (median of 7.5 *ROS1*-rearranged CTCs per 3 ml blood) in *ROS1*-negative patients was higher than that which we previously observed for *ALK* probes (median 1 *ALK*-rearranged CTC per 1 ml blood in *ALK*-negative patients) [18]. As *ROS1*-rearranged patients are rare, these results can only involve small numbers of patients: they will now require further validation in larger cohorts of *ROS1*-rearranged and negative patients to establish clear numerical thresholds for their prognostic and/or predictive potential.

Molecular analysis of CTCs can be easily repeated at different time-points during treatment to guide therapeutic decisions in a patient's treatment course. We show that qualitative and quantitative analysis of CTCs bearing *ROS1* abnormalities is possible in *ROS1*-rearranged patients undergoing ROS1-inhibitor therapy. In two patients, a reduction in *ROS1*-rearranged CTCs was consistent with radiological efficacy of crizotinib treatment, suggesting that the predictive potential of these CTCs will require further assessment in forthcoming clinical trials. In patient P3 who did not respond to treatment, the level of *ROS1*-rearranged CTCs was stable, reflecting perhaps a partial control by crizotinib although another oncogenic pathway may have driven PD.

A high level of heterogeneity of *ROS1* abnormalities was observed in CTCs from *ROS1*-rearranged patients at baseline crizotinib treatment. This heterogeneity was much greater than that observed in an isolated site corresponding tumor biopsies. We show that CTCs from *ROS1*-rearranged patients have high DNA content, as well as a high level of aneuploidy and numerical CIN. Elevated CIN may be one mechanism by which the genetic diversity of CTCs is generated in *ROS1*-rearranged patients. By generating genetic diversity, CIN may provide cells with an increased probability of acquiring tumor-promoting alterations and an increased adaptive potential when challenged by treatment. CIN has been associated with poor patient prognosis across a range of cancer types, including NSCLC, and has also been linked with intrinsic/acquired drug resistance and the probability of disease recurrence [19–22]. However, measuring CIN remains investigational and none of methods described in the present manuscript can detect emergence of secondary mutations.

High *ROS1* copy number was rarely detected in tumor specimens and the difference in *ROS1* copy numbers between tumors and CTCs observed here cannot be merely explained by the different nature of samples (paraffin tissue section versus whole cells). Spatial heterogeneity, as assessed by *ROS1* copy number between tumor and CTCs at baseline, observed in three patients

(P1, P2, P4), did not impede their subsequent disease response or control. Temporal heterogeneity of *ROS1*-rearranged CTCs during crizotinib treatment, increased in two patients in our study at the point of PD, while remaining unchanged in cells harboring only a gain. Increased heterogeneity of *ROS1*-rearranged CTCs may result in an increased potential of tumor cells targeted by crizotinib to evolve and adapt in response to treatment. Elevated CIN may thus promote the emergence of drug resistant CTC subclones with an increased metastatic capacity, offering a potential mechanism of ROS1–inhibitor–therapy resistance in *ROS1*-rearranged NSCLC tumors.

By demonstrating that *ROS1* rearrangement can be specifically detected in CTCs from *ROS1*-rearranged NSCLC patients, our study offers new perspective for diagnosing and monitoring *ROS1*-rearranged NSCLC patients eligible for crizotinib treatment. CTCs from *ROS1*-rearranged patients show considerable heterogeneity of *ROS1*-gene abnormalities and elevated numerical CIN, which may offer a mechanism by which tumor cells can escape sensitivity to ROS1-inhibitor therapy in *ROS1*-rearranged NSCLC tumors. Elevated CIN is an unreported feature of CTCs which provides a new insight into their biology.

disclosure

The authors have declared no conflicts of interest.

references

1. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363–366.
2. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol 2014; 232: 121–133.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957.

4. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385–2394.

5. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863–870.

6. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013; 18: 865–875.

7. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013; 19: 4040–4045.

8. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 20: 1963–1971.

9. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883–892.

10. Baccelli I, Schneeweiss A, Riethdorf S et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539–544.

11. Hodgkinson CL, Morrow CJ, Li Y et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897–903.

12. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573–581.

13. Krebs MG, Metcalf RL, Carter L et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129–144.

14. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–791.

15. Farace F, Massard C, Vimond N et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011; 105: 847–853.

16. Krebs MG, Sloane R, Priest L et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556–1563.

17. Ilie M, Long E, Butori C et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012; 23: 2907–2913.

18. Pailler E, Adam J, Barthelemy A et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013; 31: 2273–2281.

19. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 2012; 13: 528–538.

20. Lee AJ, Endesfelder D, Rowan AJ et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011; 71: 1858–1870.

21. Sato H, Uzawa N, Takahashi K et al. Prognostic utility of chromosomal instability detected by fluorescence in situ hybridization in fine-needle aspirates from oral squamous cell carcinomas. BMC Cancer 2010; 10: 182.

22. Nakamura H, Saji H, Idiris A et al. Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 2003; 9: 2294–2299.

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer[†]

C. Lim[1], M. S. Tsao[2], L. W. Le[3], F. A. Shepherd[1], R. Feld[1], R. L. Burkes[4], G. Liu[1], S. Kamel-Reid[2,5], D. Hwang[2], J. Tanguay[2], G. da Cunha Santos[2] & N. B. Leighl[1]*

[1]Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto; [2]Laboratory Medicine Program, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto; [3]Department of Biostatistics, Princess Margaret Cancer Centre, Toronto; [4]Division of Medical Oncology, Mount Sinai Hospital, Toronto; [5]Molecular Diagnostics Laboratory, University Health Network, Toronto, Canada

Background: Testing for *EGFR* mutations and *ALK* rearrangement has become standard in managing advanced non-small-cell lung cancer (NSCLC). However, many institutions in Europe, North America and other world regions continue to face a common challenge of facilitating timely molecular testing with rapid result turnaround time. We assessed the prevalence of biomarker testing for advanced NSCLC patients and whether testing affected the timeliness of treatment decisions.

Methods: We conducted a retrospective chart review of a random sample of one-quarter of all patients with advanced NSCLC referred to the Princess Margaret Cancer Centre from 1 April 2010 to 31 March 2013.

Results: Of 300 patients reviewed, 175 seen by medical oncology had nonsquamous NSCLC, 72% of whom had biomarker testing carried out. Patients tested for biomarkers were more likely to be female (47% versus 21%, *P* = 0.002), Asian (27% versus 6%, *P* = 0.005) and never smokers (42% versus 8%, *P* < 0.0001). Only 21% of patients with biomarker testing had results available at their initial oncology consultation. This group had a shorter median time from consultation to treatment

Correspondence to: Dr Natasha B. Leighl, Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, 5-105, 610 University Avenue, Toronto, ON, Canada M5G 2M9. Tel: +1-416-946-4645; E-mail: natasha.leighl@uhn.ca